임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
12건 표시
- 2상모집 중· Recurrent GlioblastomaA Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
리드: 바이오엔테크 · 협력: BMS
- 2상모집 중· Pancreatic Ductal Adenocarcinoma (PDAC)A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
리드: 바이오엔테크 · 협력: BMS
- 2상모집 예정· CRC (Colorectal Cancer)PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
협력: 바이오엔테크
- 2상모집 중· Solid TumorsDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
협력: 바이오엔테크
- 2상모집 중· Muscle-invasive Urothelial CarcinomaA Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
리드: 로슈 · 협력: 바이오엔테크
- 2상모집 중단 (진행 중)· Locally Advanced Breast CancerSafety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
리드: 바이오엔테크 · 협력: BMS
- 2상모집 중단 (진행 중)· Extensive-stage Small-cell Lung CancerSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
리드: 바이오엔테크
- 2상모집 중· Adenocarcinoma, Pancreatic DuctalA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
리드: 로슈 · 협력: 바이오엔테크
- 2상모집 중단 (진행 중)· Advanced Non-Small Cell Lung CancerA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
리드: 리제네론 · 협력: 바이오엔테크
- 2상모집 중단 (진행 중)· Colorectal Cancer Stage IIA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
리드: 바이오엔테크 · 협력: 로슈
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.